Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a pill replace CPAP for sleep apnea heart risks?

NCT ID NCT00777985

Disease control Sponsor: University Hospital, Grenoble Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 19 people with sleep apnea and mild high blood pressure. It compared a drug called bosentan to the standard CPAP machine to see if the drug could lower blood pressure just as well. The goal was to find a simpler way to manage heart risks in sleep apnea patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

19 people

The number who actually took part.

Start date

Dec 2007

Finished

Jan 2012

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Documented obstructive sleep apnea * with untreated mild systemic hypertension Exclusion Criteria: * pregnancy or lactation * daytime alveolar hypoventilation * severe arterial hypertension (systolic pressure \> 180 mmHg; diastolic pressure \> 110 mmHg) * treatment with anti-hypertensive drugs * cardiovascular disorder other than mild hypertension * severe daytime sleepiness (score on the EPWORTH sleepiness scale ≥15) or at-risk occupation * contra-indication to nCPAP treatment * known allergy to bosentan * active treatment with a drug whose efficacy is reduced by cytochromes P450, 2C9, 3A4 and2C19 isoenzyme activation * active treatment with a drug acting on systemic arterial blood pressure or endothelial function * liver or kidney dysfunction

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

benign essential hypertension hypertensive disorder obstructive sleep apnea syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension Obstructive sleep apnea

Contacts and locations

Locations

  • CHU de Grenoble

    Grenoble, 38043, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.